Navigation Links
Personal Genome Diagnostics and MolecularMD Collaborate to Provide Advanced Genomic Testing Services to Cancer Drug Developers
Date:10/25/2013

BALTIMORE, Oct. 25, 2013 /PRNewswire/ -- Personal Genome Diagnostics Inc. (PGDx), today announced that it will collaborate with MolecularMD to market a suite of comprehensive personalized medicine services to oncology researchers and drug developers, adding PGDx's expertise in Next-Generation Sequencing (NGS)-based cancer biomarker discovery to MolecularMD's capabilities in the development, validation and global delivery of cancer companion diagnostics. The collaboration is designed to provide a unique specialized service to the pharmaceutical and biotechnology industry, seamlessly spanning the entire spectrum of genomic and clinical trial services used in new drug R&D and clinical development. Under the terms of the agreement, the two companies will co-market each other's services to their pharmaceutical and biotechnology customers.

PGDx provides advanced genome mapping services and analyses to oncology researchers, clinicians and patients. It employs cancer exome analysis, which enables comprehensive, reliable and unbiased genome-wide identification of cancer-related mutations. The company's proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics.

MolecularMD provides molecular diagnostics products and services to pharmaceutical and biotechnology drug developers. Its capabilities range from specialty molecular testing services performed in its CLIA-certified and CAP-accredited laboratory to development of companion diagnostics that support new drug registrations. It also provides NGS services for clinical trials, including standard and custom-designed panels that can profile gene alterations relevant to therapeutic response or resistance.

"PGDx focuses on unbiased NGS-based approaches that are most relevant in the early stages of drug discovery and development, which complements MolecularMD's capabilities in the development of companion diagnostics for specific cancer biomarkers. This collaboration will now enable the two companies to provide a complete spectrum of genomic services to drug developers," said Antony Newton, Chief Commercial Officer of PGDx. "We share a mission of applying advances in cancer genomics to accelerate new drug development and achieve improved patient outcomes, and we expect this agreement to benefit our customers and ultimately, cancer patients."

"PGDx has unique capabilities that supplement the growing menu of advanced genomic services MolecularMD provides to oncology drug developers," noted Glenn A. Miller, PhD, Executive Vice President and Chief Technology Officer of MolecularMD. "The combination of our distinctive sets of expertise and common commitment to translating progress in cancer genomics into high quality tools for drug developers and clinicians should make this a valuable collaboration."

The scientific founders of PGDx, Luis Diaz, MD, and Victor Velculescu, MD, PhD, are internationally recognized leaders in cancer genomics at Johns Hopkins University and have extensive experience in the practical application of advanced genomic technologies to drug development and clinical practice. 

About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced genome-mapping services and analyses to oncology researchers, clinicians and patients. The company was founded in 2010 by international leaders in cancer genetics at Johns Hopkins University. PGDx conducts patient-specific analyses aimed at identifying the unique genomic alterations in tumors and linking them to the underlying biology. PGDx employs cancer exome analysis, which enables comprehensive and reliable genome-wide identification of cancer-related mutations. The company's proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics. PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.

About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Its tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD incorporates gold-standard and innovative technologies in providing its partners with the highest quality results. Tests are designed to meet clinical trial needs, and MolecularMD has appropriate systems and standards in place to enable development of companion diagnostic tests in conjunction with partners' novel anticancer agents. A private company based in Portland, Oregon, MolecularMD was founded by Dr. Brian Druker, director of the Knight Cancer Institute at Oregon Health & Science University, and Sheridan G. Snyder, entrepreneur and founder of Genzyme Corporation. For more information, visit http://molecularmd.com/.Contacts: Personal Genome Diagnostics

Media:Antony Newton

BLL Partners, LLCChief Commercial Officer

Barbara Lindheim410 849-9189

212 584-2276anewton@personalgenome.com

blindheim@bllbiopartners.com


'/>"/>
SOURCE Personal Genome Diagnostics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
2. 2013 SharpBrains Virtual Summit to Discuss Latest on Digital Brain Health, Brain Fitness, Personal Health
3. Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
6. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
7. The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris
8. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
9. NYSCF scientists create personalized bone substitutes from skin cells
10. Lucintel’s Analysis of Growth Opportunities in Global Polymer Ingredients Used in Personal Care Industry: Market to Reach $3,495 Million by 2017
11. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Last week, Callan Capital, an integrated wealth management ... The Future of San Diego Life Science event at the Estancia La Jolla Resort ... the event with speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and ...
(Date:5/23/2016)... , May 23, 2016 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the second quarter of 2016. The cash ... about July 29, 2016 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
(Date:5/20/2016)... ... 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural cell ... treat the disease. Surviving Mesothelioma has just posted an article on the new study. ... based their mesothelioma study on the fact the Manumycin A, a derivative of Streptomyces ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):